How to Vet a Korean Translation Partner for Clinical and Financial Content: A 2026 Checklist

Hyunjae Jung · 2026-06-11

If you only remember one thing from this post: for high-stakes Korean content, vet the process, not the sample. A polished sample tells you what a vendor can do once. Documented QA tells you what they do every time — and when a regulator, auditor, or investor is reading the output, “every time” is the only standard that matters.

Here is the checklist we recommend to companies buying Korean↔English translation for clinical or financial documents in 2026, drawing on a decade of translation work inside these document types.

1. Ask what happens when (not if) AI is in the pipeline

Machine translation followed by human post-editing is the industry standard now — pretending otherwise is a red flag in itself. The questions that separate vendors:

Where does the human review sit, and what does it check? For clinical and financial content, you want explicit verification of numbers, units, dosages, and dates — not just fluency.
Is your content used to train external AI models? Get the answer in writing. Disclosure documents and trial protocols are confidential by definition.
Who is accountable, by name? Anonymous vendor pools diffuse responsibility. A named linguist with verifiable credentials concentrates it.

2. For clinical content: audit-readiness is the bar

Sponsors and regulators increasingly ask for evidence about the translation itself: who translated it, what their qualifications are, which version was approved and when. If your vendor cannot produce a translation record — linguist, dates, versions, sign-offs — your study documentation has a gap.

For participant-facing documents (informed consent forms above all), ask whether back-translation with reconciliation is available. Many IRBs and ethics committees expect it.

3. For financial content: terminology governance beats speed

Korean listed companies now face mandatory English disclosure on tight timelines — as of May 2026 the obligation covers KOSPI companies above ₩2 trillion in assets, expanding to the entire KOSPI market in March 2027. The failure mode is rarely a missed deadline; it is a corrected filing caused by an inconsistent term or a wrong figure, and corrections stay on the record.

Ask the vendor: do you maintain a company-specific glossary (account titles, officer titles, recurring phrases)? Is it applied across all document types — filings, annual reports, IR decks? Can you meet the three-business-day turnaround once templates are in place?

4. The quick checklist

Domain specialization, with document types named (protocols, ICFs, CSRs / filings, IFRS notes) — not “all fields.”
Documented QA steps: who checks numbers, units, and terminology, and in what order.
Translation records available for audits (linguist, versions, dates).
Back-translation option for participant-facing clinical documents.
Written confidentiality terms, including a no-AI-training commitment for your content.
A company glossary as a deliverable, not an internal secret.
A named, credentialed linguist who signs the work.

Why this matters more in 2026

AI has made baseline translation nearly free — which means the value, and the risk, has moved entirely to the verification layer. Buyers who vet that layer get AI speed with human accountability. Buyers who don’t are publishing unreviewed machine output with their company’s name on it.

Seoulnatives is a Seoul-based Korean↔English localization studio founded in 2018, specializing in clinical, financial, and brand-critical content. Questions about a Korean-language project? Write to translation@seoulnatives.com.